Table 3.
Developmental anomalies in offspring stratified by the maternal polycystic ovary syndrome (PCOS) diagnosis.
| Congenital anomalies | Unadjusted OR | 95% CI | Adjusted OR | 95% CI |
|---|---|---|---|---|
| Any anomalies | 1.30 | 1.12–1.51 | 1.20 | 1.03–1.40 |
| Major anomalies | 1.22 | 1.03–1.44 | 1.14 | 0.96–1.35 |
| Cardiovascular | 1.56 | 1.16–2.10 | 1.37 | 1.01–1.87 |
| Urogenital | 1.39 | 1.06–1.82 | 1.36 | 1.03–1.81 |
| Other | 1.43 | 0.98–2.08 | 1.30 | 0.88–1.93 |
| Non-cardio and urogenital | 1.13 | 0.93–1.37 | 1.05 | 0.86–1.28 |
Source: Reproduced with permission from The American College of Obstetricians and Gynecologists from Doherty et al.6 Published by Wolters Kluwer Health, Inc.
OR: odds ratio; CI: confidence interval.
The effects of PCOS on the risk of developmental anomalies summarized with crude and adjusted odds ratios (ORs) and their 95% confidence intervals (CIs) obtained in the logistic regression analyses are shown. All statistically significant effects of PCOS in the adjusted comparisons are shown in boldface.
All outcomes adjusted for IVF, multiple pregnancy, maternal age (<20, 20–29, 30–39, 40+), smoking during pregnancy (yes, no or unreported), gestational diabetes, male gender, current age of offspring in years (<1, 1–2, 3–6, 6+).